undamentalytics Newsletter
Sign in

Opus Genetics, Inc. balance sheet

At the end of fiscal 2025, Opus Genetics, Inc. had total assets of $50.2m, total liabilities of $34.9m and shareholders' equity of $15.3m. It held $45.1m in cash against $1.1m of debt: net cash of $44.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents712101319216254351304589
Receivables——————0011421
Total current assets—16121419218264954375093
Total assets—16141520218264954375093
Accounts payable—————01212332
Deferred revenue (current)—————2———————
Total current liabilities—————934341188
Short-term debt——————010————
Long-term debt——————————0135
Total debt00000501000135
Total liabilities—63579314341135106
Shareholders' equity510111013−8−13224650715−13
Non-controlling interests and other (assets − liabilities − equity)——————————19——
Net debt (negative = net cash)−7−12−10−13−193−16−24−43−51−30−44−54
Shares outstanding—84m———3m——21m24m32m70m83m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRBU vs IRDIRD vs RLAYHYFT vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Opus Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Opus Genetics, Inc.